Prohost BioTechnology
Biotechnology Research and Investment

Prohost Letter #357 MARCH 16, 2014

BIOTECH STOCK PRICE TARGETS

IT'S ALL ABOUT FAIR EVALUATION

Logically speaking, nothing should change our stock price near-term targets except unexpected circumstances that would positively or negatively impact the firm's values.

Prohost Stock Price targets are meticulously calculated except for surprises.

Analysts' upgrades and downgrades definitely move stock prices up and down, but for a few days only. They cannot affect our targets.

BEAR MARKETS

Do not differentiate overvalued from undervalued firms.

They bring all stock prices down.

They result in a correction for the overvalued stocks but miscalculation of the undervalued or fairly valued stocks before the market plunges.

Here we see investment opportunities in the undervalued excellent firms. This is especially true for growth firms whose growth has, and continue to outperform the markets.

The Sell Side And Buy Side Analysts

Negative investors and analysts advocate selling stocks while positive analysts and investors advocate the opposite.

When the biotechnology stocks rally for a substantial amount of time, ***short sellers forecast a near burst of the bubble.*** *They spread fear among investors, which makes them feel they must get their investments out of the bubble before the whole thing collapses. On the other side of the coin, the long on stocks forget themselves and continue to advocate buying of stocks that have become residents of the overbought zone.*

Facts

The unprecedented speed of the advancement in life sciences and the tremendous changes that are due to occur in the field of agriculture and clinical pharmacology, the collapse of the industry should be the last thought to be allowed to cross rational minds

Imagine what would happen if illumine, Gilead, Amgen, Biogen Idec, Regeneron, Celgene, Vertex and other small and large creative biotechnology firms collapse?

It Is ALL About Targets

FIRMS & SYMBOLS	Price & Date Stocks Picked	3/14/14 Price	Market Cap.	1 st Targets	2016 Targets	Observations AND DECISIONS
TOP-TIER FIRMS. GENERAL DRUG DEVELOPING FIRMS						
GILEAD (GILD)	$20.75 On 3/18/11	$75.05	115.5 B	$100	$200	NO CHANGE IN TARGETS. You will know why when you read the details in the complete letter in the making
AMGEN (AMGN)	$52.94 On 3/18/11	$122. 54	92.95 B	$150	$200	NO CHANGE IN TARGETS See the complete Prohost Letter Tomorrow.
REGENER. (REGN)	$38.81 On 03/18/11	$329.50	32.67 B	$350 R	$500	1st TARGET RAISED FROM $310 TO $350 2016 TARGET LEFT UNCHANGED
VERTEX (VRTX)	$44.39 On 03/18/11	$78.32	18.47 B	$85	$160	1st TARGET LEFT UNCHANGED 2016 TARGET LEFT UNCHANGED
ILLUMINA (ILMN)	$62.11 On 03/18/11	$164.72	21.12 B	$150	$400	1st TARGET RAISED FROM $150 TO $350 2016 T. RAISED FROM $400 to $500
JAZZ (JAZZ)	$29.2 On 03/18/11	$149.22	8.66 B	$200	$250	1st TARGET UNCHANGED 2016 T UNCHANGED
CANCER COMPANIES. EACH WITH ONE MARKETED PRODUCT						
PHARMAC. (PCYC)	$15.25 On 11/5/11	$123.08	9.20 B	$180	$250	1st TARGET LOWERED TO $140 2016 TARGET LOWERED TO $200
INCYTE (INCY)	$14.29 On 03/18/11	$61.42	10.17 B	$75	$120	1st TARGET UNCHANGED 2016 TARGET UNCHANGED
IMMUNOG (IMGN)	$8.50 On 03/18/11	$15.82	1.35 B	$25	$55 R	1st TARGET UNCHANGED 2016 TARGET UNCHANGED
ARIAD ARIA)	$6.40 On 03/18/11	$8.17	1.52 B	$14	$28	1st TARGET UNCHANGED 2016 TARGET UNCHANGED
Seattle Gen. (SGEN)	$14.28 On 03/18/11	$50.29	6.18 B	$70	$120	1st TARGET UNCHANGED 2016 TARGET UNCHANGED
GENERAL DRUG DEVELOPER						
Theravance (THRX)	$24.03 On 03/12/13	$33.59	3.80 B	$50	$70	1st TARGET UNCHANGED 2016 TARGET UNCHANGED
ANTISENSE PRODUCTS						
ISIS (ISIS)	$8.62 On 03/18/11	$45.36	5.33 B	$85	$125	1st TARGET UNCHANGED 2016 TARGET UNCHANGED
ALNYLAM (ALNY)	$10.80 On 01/25/12	$71.19	4.55 B	$150	$290	1st TARGET UNCHANGED 2016 TARGET UNCHANGED
SAREPTA (SRPT)	$28.33 On 11/21/12	$27.12	1.02 B	$40	$60	1st TARGET UNCHANGED 2016 TARGET UNCHANGED
SANGAMO (SGMO)	$7.19 On 3/18/11	$23.04	$1.45 B	$22	$35	1st T. RAISED FROM $22 TO $40 2016 T. RAISED FROM $35 TO $60
PLEURISTEM (PSTI): MIGHT BE OFFICIALLY CONFIRMED AS A PICK IN THE NEXT LETTER						

SRPT: Bought at **$28.33** on 11/21/12 Sold it at **$40**. Bought it back on Jan.28, 2014 at $25.15
SGMO Read The News and other Article about this firm in the Prohost Complete Letter Tomorrow after market closed
SGEN soared lately and today. The prices in the table are those of Friday
THRX has good news that will be posted and explained tomorrow.

PORTFOLIO #2

Firms and Symbols	Date Picked and Price	Price 3/14/14	Market Cap	1st Target	2016 Target	Observations and Decisions
NEWELY PICKED FIRMS						
PORTOLA (PTLA)	$26.65 On 2/22/2014	$27.22	1.12 B	$40	$80	READ PAST ISSUE #356. TARGETS UNCHANGED
NEKTAR	$12.84 On 1/27/14	$13.43	1.70 B	$!6	$35	PROFILE WILL BE POSTED IN PROHOST LETTER TOMORROW. TARGETS UNCHANGED
ENANTA (ENTA)	$20.75 On 11/25/13	$40.85	750.13 M	$45	$55	OUTPERFORMED SINCE BOUGHT. TARGETS UNCHANGED
BIOCRYST (BCRX)	$9.40 On Jan. 8 2014	$11.11	659.76. M	$18	$32	TARGETS UNCHANGED. APPROVAL FOR A FLU VACCINE EXPECTED
ORAMED (ORMP)	SOLD	~~$24.38~~	~~237.58 M~~			SOLD AND SUBSTITUTED WITH IMGN
COMPUGEN CGEN	$10 On Jan. 8, 2014	$11.19	463.34. M	$18	$28	NEW Selection. New Targets. Great drug Discovery Engine.
DEVELOPMENT STAGE CANCER COMPANIES						
EXELXIS (EXEL)	$11.35 On 3/18/11	$6.27	$1.22 B	$16	$35	TARGETS UNCHANGED WILL SOON ANNOUNCE RESULTS FROM CLINICAL TRIALS
ARRAY (ARRY)	$3.00 On 3/18/11	$5.11	$641.08 M	$12	$15	TARGETS UNCHANGED WILL SOON ANNOUNCE GOOD NEWS
ENDOCYTE (ECYT)	$17.45 On 8/05/13	$13.65	$483.86 M	$25	$40	READ TOMORROW OUR ASSESSMENT
SYNTA (SNTA)	$4.38 On 2/2/12	$5.45	$373.12 M	$8	$14	1st TARGET LOWERED TO $5 2016 TARGET RAISED TO $!8
SUNESIS (SNSS)	$2.48 On 3/29/12	$7.01	$421.26 M	$8	$15	TARGETS UNCHANGED STOCK OUTPERFORMED
GENERAL DRUG DEVELOPERS AND DRUG DELIVERY						
XOMA (XOMA)	$4.51 On 3/18/11	$6.02	$641.57 M	$12	$22	TARGETS UNCHANGED STOPPING ONE INDICATION OF ITS LEAD DRUG WILL NOT IMPACT LONG TERM PERFORMANCE
HALOZYME (HALO)	$6.57 On 3/25/13	$13.56	$1.54 B	$25	$35	TARGETS UNCHANGED
THERAPEUTIC VACCINES FOR CANCER AND OTHER DISEASES						
CELLDEX (CLDX)	$25.65 On 11/11/13	$23.14	$2.07 B	$20	-------	WARNING: 1st target lowered to $20 We SOLD most of the stock and kept some stock to accumulate if and when concrete data would surface.
DENDREON (DNDN)	$7.56 On 1/3/12	$2.99	$458.53 M	$6-$7	$9	TARGETS UNCHANGED
AGENUS (AGEN)	$5.64 On 3/18/11.	$4.32	$288.59 M	$10	$30	TARGETS UNCHANGED. IMPORTANT NEWS WILL BE POSTED TOMORROW IN THE COMPLETE LETTER.
PRENATAL DIAGNOSIS FIRMS						
SEQUENOM (SQNM)	$5.92 On 3/18/11	$2.29	$266.32	$4	$6	ILLUMINA'S HAS BECOME DANGEROUS FOR THIS FIRM. ACQUISITION IS A REMOTE POSSIBILITY. WE SELL NOW AND BUY ARRY OR AGEN

NOTES

READ THE COMPLETE LETTER TOMORROW

FORWARD-LOOKING: Material presented here is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. Further, these are our 'opinions' and we may be wrong. We may have positions in securities mentioned in this article. You should take this into consideration before acting on any advice given in this article. If this makes you uncomfortable, then do not listen to our thoughts and opinions. The contents of this article do not take into consideration your individual investment objectives so consult with your own financial adviser before making an investment decision. Investing includes certain risks including loss of principal.